September 09, 2015
Gilead Prices $10 Billion of Senior Unsecured Notes
$1,000 millionof 1.850% senior notes maturing in 2018
$2,000 millionof 2.550% senior notes maturing in 2020
$1,000 millionof 3.250% senior notes maturing in 2022
$2,750 millionof 3.650% senior notes maturing in 2026
$1,000 millionof 4.600% senior notes maturing in 2035
$2,250 millionof 4.750% senior notes maturing in 2046
The senior notes are rated A- by Standard & Poor’s and A3 by Moody’s.
The offering is expected to close
Gilead intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of debt, working capital, payment of dividends and the repurchase of its outstanding common stock pursuant to its authorized share repurchase program.
Merrill Lynch, Pierce, Fenner & Smith Incorporated
J.P. Morgan Securities LLC
|222 Broadway, 11th Floor||383 Madison Ave.|
|New York, NY 10038||New York, NY 10179|
|Attention: Prospectus Department||Attn: Investment Grade Syndicate Desk|
|(800) 294-1322||(212) 834-4533|
An electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission’s website at http://www.sec.gov/.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the current
market demand for these types of securities and the securities of
Gilead, Gilead’s ability to consummate the offering in the currently
anticipated timeframe or at all and the negotiations between Gilead and
the underwriters. These risks, uncertainties and other factors could
cause actual results to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks that could impact the
offering are described in detail in Gilead’s Quarterly Report on Form
10-Q for the quarter ended
Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)